Rapid communication · 29 May 2025
Conference abstractPublished 2014
UIC Experience: Human islet transplantation for treatment of type 1 Diabetes and biological license application
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Management of type 1 diabetes is burdensome both to the individual and to society as a whole, costing over 100 billion dollars annually. Near perfect control of blood glucose levels can be restored by islet transplantation, without the risk of serious hypoglycemic episodes that are associated with intensive insulin therapy. Islet cell transplantation offers immense promise as a cell-based, functional cure for diabetes. The UIC islet transplant research team successfully completed a Phase 1/2 clinical trial and currently undertaking two phase 3 clinical trials. A total of 29 participants have been successfully transplanted and have achieved insulin independence after 1-3 islet transplants. Although the duration of islet graft survival cannot be predicted, participants report freedom from glycemic labiality and life-threatening hypoglycemic episodes. The required sample size for a single arm Phase 3 trial is in the range of 20-30 patients. According to this, UIC has approached the end of the trial and is in the process of filing a licensure that will make this treatment a standard care for type 1 diabetes. In the US, in order to introduce a biological product into interstate commerce, a Biologics license is required. Granting of the license certifies that the biological product is safe, pure, and potent; and the facility in which it is manufactured meets all standards designed to ensure that it continues to be safe, pure, and potent.This is a remarkable achievement considering that few academic institutions hold a licensure for biological product in the USA.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Diabetes & Metabolism.
Rapid communication · 29 May 2025
Genetic and epigenetic markers for gdm risk
Short communication · 29 May 2025
Metabolic syndrome: Diet, timed eating, supplements
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Diabetes & Metabolism
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Barbara Barbaro”